Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

ProBioGen AG. (6/26/18). "Press Release: ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform". Berlin & Basel.

Organisations Organisation ProBioGen AG
  Group Minapharm (Group)
  Organisation 2 Nouscom AG
  Group Nouscom (Group)
Products Product AGE1.CR duck cell line
  Product 2 vaccine
Index term Index term Nouscom–Minapharm: cell line, 201806– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines
Persons Person Sandig, Volker (ProBioGen 201004 promoted CSO since 2000 at ProBiogGen before Merck US)
  Person 2 Colloca, Stefano (Nouscom 201806 CTO)
     


Proprietary Duck Cell Line Serves as Large-Scale Production-Suitable Cell Substrate


ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins, virus production and viral vector technologies and Nouscom AG, an oncology company dedicated to development of immunotherapies, today jointly announced signing a license agreement. Under the terms of the agreement, Nouscom will gain access to ProBioGen’s proprietary production platform based on the AGE1.CR® duck retina cell line for production of its viral vectored vaccines.

ProBioGen’s CSO, Dr Volker Sandig said: “We have developed the AGE1.CR® designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom´s highly innovative vaccine approach will greatly benefit from it.”

Nouscom’s CTO, Dr Stefano Colloca added: “We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company.”


About ProBioGen AG

ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins viral vectors and vaccine technologies. Combining both state-of-the-art protein and virus platforms, based on ProBioGen’s CHO.RiGHT® and AGE1.CR® expression and manufacturing platforms, respectively, together with intelligent product-specific technologies, yield biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.

All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.


About Nouscom AG

Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.


Contacts

ProBioGen AG:
Dr Gabriele Schneider
Chief Business Officer
Goethestr. 54
13086 Berlin, Germany
+49 (0)30 924 006-0
cmo@probiogen.de
www.probiogen.de

NousCom
Marina Udier, PhD
Chief Operating Officer
+41 61 201 1835
info@nouscom.com
www.nouscom.com

   
Record changed: 2018-07-21

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Minapharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top